Abstract: FR-PO211
Association of Thyroid Function with Prevalence and Development of CKD
Session Information
- CKD: Epidemiology, Risk Factors, Prevention - II
October 26, 2018 | Location: Exhibit Hall, San Diego Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: CKD (Non-Dialysis)
- 1901 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention
Authors
- Toda, Akiko, Toranomon Hospital, Tokyo, Japan
- Tsuji, Hiroshi, Toranomon Hospital, Tokyo, Japan
- Hara, Shigeko, Toranomon Hospital, Tokyo, Japan
Background
Previous cross-sectional studies indicated an association between hypothyroidism and kidney dysfunction, but few studies have investigated aboutthyroid dysfunction and chronic kidney disease (CKD), especially whether thyroid dysfunction is a risk factor for CKD development.
Methods
Using the data of annual health check-ups, we evaluated a relationship of thyroid dysfunction with CKD prevalence and development by a multivariate logistic regression analysis. In cross-sectional and longitudinal studies, 16,390 subjects and 7,609 subjects were analyzed, respectively. We categorized the subjects into four groups based on their serum thyroid-stimulating hormone (TSH) concentrations;below-normal (TSH <0.54 mU/L), lower-normal (0.54–2.40 mU/L), higher-normal (2.40–4.26 mU/L) and above-normal (>4.26 mU/L). As covariate factors, age, gender, obesity, hypertension, dyslipidemia, hyperuricemia, diabetes mellitus, proteinuria, and hematuria were adjusted in cross-sectional study. In longitudinal study, the baseline eGFR was added to the covariate factors of the cross-sectional study.
Results
The cross-sectional study revealed a positive correlation between the TSH concentration and CKD prevalence. Compared with the lower-normal TSH group, the odds ratios (ORs) and 95% confidence intervals (CI) of CKD prevalence were 0.609 (0.452–0.821, p= 0.001) for the below-normal group, 1.492 (1.332–1.672, p<0.001) for the higher-normal group, and 1.900 (1.568–2.302, p<0.001) for the above-normal group. The longitudinal study revealed that the risk of CKD development within three years was significantly higher in the above-normal TSH group compared with the lower-normal TSH group: OR 1.578, 95% CI 1.016–2.451, p= 0.042. However, no significances of CKD development risk in the below-normal TSH group and the higher-normal TSH group were observed.
Conclusion
Our data indicated that a higher TSH concentration has a positive correlation with CKD prevalence, and that a high TSH concentration is a risk factors for CKD development. These results suggest thatthyroid function screening might be informative in patients whose eGFR declines without a clear cause, and thyroid hormone replacement therapy for hypothyroidism patients could have an effect on preventing CKD development.